Form4insider filings, from the source

SEC Form 4 · accession 0001193805-15-001723

CytomX Therapeutics, Inc. · CTMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
DEERFIELD MANAGEMENT CO
10% Owner · Other
Deerfield Mgmt L.P.
10% Owner · Other
James E Flynn
10% Owner · Other
Deerfield Mgmt III, L.P.
10% Owner · Other
Period of report
Oct 14, 2015
Accepted (ET)
Oct 14, 2015 · 12:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3Oct 14, 2015C160,512—A160,512IThrough Deerfield Private Design Fund III, L.P.
Common StockF1,F2,F3Oct 14, 2015C160,512—A160,512IThrough Deerfield Special Situations Fund, L.P.
Common StockF2,F3Oct 14, 2015P510,512$12.00A671,024IThrough Deerfield Private Design Fund III, L.P.
Common StockF2,F3Oct 14, 2015P114,488$12.00A275,000IThrough Deerfield Special Situations Fund, L.P.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series D Convertible Preferred StockF1,F2,F3—Oct 14, 2015C160,512D——Common Stock160,5120I
Series D Convertible Preferred StockF1,F2,F3—Oct 14, 2015C160,512D——Common Stock160,5120I

Explanation of responses

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Avalanche Biotechnologies, Inc. filed with the Securities and Exchange Commission on July 30, 2014 by Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.